Search

Boston Scientific Corp.

Closed

SectorHealthcare

51.81 0.12

Overview

Share price change

24h

Current

Min

51.68

Max

52.75

Key metrics

By Trading Economics

Income

-437M

904M

Sales

239M

5.4B

P/E

Sector Avg

19.945

57.002

EPS

0.86

Profit margin

16.612

Employees

59,000

EBITDA

-214M

1.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.41% upside

Dividends

By Acuity

Next Earnings

28 paź 2026

Market Stats

By TradingEconomics

Market Cap

5.5B

73B

Previous open

51.69

Previous close

51.81

News Sentiment

By Acuity

41%

59%

144 / 340 Ranking in Healthcare

Boston Scientific Corp. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions finishing higher. No specific news was identified.

13 sie 2026, 23:01 UTC

Social Media

Boston Scientific shares are higher in after-market trading, buoyed by social media discussions of the CEO's $9 million stock purchase amid a significant year-to-date decline.

12 sie 2026, 23:06 UTC

Boston Scientific Corp shares are modestly higher in after-market trading. The stock remains significantly above its 20-day moving average.

11 sie 2026, 23:41 UTC

Boston Scientific Corp shares are lower in after-market trading, showing unusual volatility and reflecting a broader trend of weakness since Tuesday's close.

10 sie 2026, 23:06 UTC

Boston Scientific shares are trading higher in after-market hours, amid mixed market sentiment influenced by geopolitical tensions, particularly concerning the Strait of Hormuz.

8 sie 2026, 00:01 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting gains since Friday's close and remaining above their 20-day moving average.

7 sie 2026, 23:21 UTC

Boston Scientific shares are higher in after-market hours following a Labor Department report showing a decline in non-farm payroll employment, reducing interest rate hike expectations.

6 sie 2026, 23:01 UTC

Boston Scientific Corp shares are higher during after-market hours, reflecting a generally strong performance backdrop amid resilient labor market data.

5 sie 2026, 23:02 UTC

Social Media
News

Boston Scientific Corp shares rose in after-market trading following CEO Mahoney's purchase of 186,240 shares at an average price of $48.33.

4 sie 2026, 19:36 UTC

News

Boston Scientific shares are higher, supported by strong organic revenue growth and rising free cash flow margin, despite recent economic data pressures.

3 sie 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting positive momentum. Broader economic news shows increased growth in the manufacturing sector.

31 lip 2026, 22:52 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting positive market sentiment from strong earnings by major tech companies.

30 lip 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

29 lip 2026, 23:51 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting broader market gains. No specific news has been identified to explain the movement.

28 lip 2026, 23:52 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting a steady increase since Tuesday's close despite broader market concerns, particularly in Asia.

27 lip 2026, 23:02 UTC

News
Social Media

Boston Scientific plans a restructuring with pre-tax charges of $700 million to $800 million, leading shares lower in after-market hours.

25 lip 2026, 00:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

24 lip 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

22 lip 2026, 20:06 UTC

Correlated Moves

Boston Scientific reported first-quarter adjusted EPS of $0.43, missing estimates. Shares are trading lower amid cautious market sentiment and Stryker's decline.

21 lip 2026, 23:06 UTC

Boston Scientific Corp shares are higher in after-hours trading, reflecting a modest uptick following Tuesday's close. The stock remains below its 20-day moving average.

20 lip 2026, 23:01 UTC

Boston Scientific shares are higher in after-market trading, reflecting notable strength since Monday's close, despite no specific news driving the movement.

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

20.41% upside

12 Months Forecast

Average 62.41 USD  20.41%

High 89 USD

Low 50 USD

Based on 24 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

21

Buy

3

Hold

0

Sell

Sentiment

By Acuity

144 / 340 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat